{
    "PMC8668943_3": [
        {
            "subject": {
                "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                "adjusting for": "birthweight and FCGR2C genotypes",
                "Fc\u03b3RIIc copy number": "1 copy",
                "statistical representation": "Univariate OR (95% CI)"
            },
            "measures": "[Univariate OR, P-value]",
            "outcomes": "[0.29 (0.12-0.71), 0.007]"
        },
        {
            "subject": {
                "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                "adjusting for": "birthweight and FCGR2C genotypes",
                "Fc\u03b3RIIc copy number": "1 copy",
                "statistical representation": "Adjusted OR"
            },
            "measures": "[Adjusted OR, P-value]",
            "outcomes": "[0.37 (0.15-0.90), 0.029]"
        },
        {
            "subject": {
                "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                "adjusting for": "birthweight and FCGR2C genotypes",
                "Fc\u03b3RIIc copy number": "2 copies",
                "statistical representation": "Univariate OR (95% CI)"
            },
            "measures": "[Univariate OR]",
            "outcomes": "[Ref]"
        },
        {
            "subject": {
                "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                "adjusting for": "birthweight and FCGR2C genotypes",
                "Fc\u03b3RIIc copy number": "2 copies",
                "statistical representation": "Adjusted OR"
            },
            "measures": "[Adjusted OR]",
            "outcomes": "[Ref]"
        },
        {
            "subject": {
                "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                "adjusting for": "birthweight and FCGR2C genotypes",
                "Fc\u03b3RIIc copy number": "\u22653 copies",
                "statistical representation": "Univariate OR (95% CI)"
            },
            "measures": "[Univariate OR, P-value]",
            "outcomes": "[0.99 (0.63-1.57), 0.978]"
        },
        {
            "subject": {
                "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                "adjusting for": "birthweight and FCGR2C genotypes",
                "Fc\u03b3RIIc copy number": "\u22653 copies",
                "statistical representation": "Adjusted OR"
            },
            "measures": "[Adjusted OR, P-value]",
            "outcomes": "[0.74 (0.43-1.27), 0.275]"
        }
    ],
    "PMC5817808_2": [
        {
            "subject": {
                "study": "Essos hospital center PMTCT program",
                "analysis": "survival at 24 months",
                "population": "HIV exposed infants",
                "mode of feeding": "Exclusive replacement feeding",
                "unadjusted HR": "Ref",
                "unadjusted p-value": "Ref",
                "adjusted HR": "Ref",
                "adjusted p-value": "Ref"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study": "Essos hospital center PMTCT program",
                "analysis": "survival at 24 months",
                "population": "HIV exposed infants",
                "HIV- Status": "Negative",
                "unadjusted HR": "Ref",
                "unadjusted p-value": "Ref",
                "adjusted HR": "Ref",
                "adjusted p-value": "Ref"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study": "Essos hospital center PMTCT program",
                "analysis": "survival at 24 months",
                "population": "HIV exposed infants",
                "birth weight": "<2500 g",
                "unadjusted HR": "Ref",
                "unadjusted p-value": "Ref",
                "adjusted HR": "Ref",
                "adjusted p-value": "Ref"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study": "Essos hospital center PMTCT program",
                "analysis": "survival at 24 months",
                "population": "HIV exposed infants",
                "test": "Global Schoenfeld residuals test",
                "p-value": "0.23"
            },
            "measures": "[]",
            "outcomes": "[0.23]"
        }
    ],
    "PMC5574138_3": [
        {
            "subject": {
                "analysis": "meta-regression",
                "covariate": "Length of follow-up",
                "statistical representation": "95% confidence interval"
            },
            "measures": "[estimate, standard error, 95% confidence interval]",
            "outcomes": "[-0.0138, 0.0666, (-0.1322, 0.1046)]"
        },
        {
            "subject": {
                "analysis": "meta-regression",
                "covariate": "Median CD4 count",
                "statistical representation": "95% confidence interval"
            },
            "measures": "[estimate, standard error, 95% confidence interval]",
            "outcomes": "[-0.0034, 0.0066, (-0.0150, 0.0079)]"
        },
        {
            "subject": {
                "analysis": "meta-regression",
                "covariate": "Median age",
                "statistical representation": "95% confidence interval"
            },
            "measures": "[estimate, standard error, 95% confidence interval]",
            "outcomes": "[0.0415, 0.0503, (-0.1013, 0.0755)]"
        },
        {
            "subject": {
                "analysis": "meta-regression",
                "covariate": "Year of publication",
                "statistical representation": "95% confidence interval"
            },
            "measures": "[estimate, standard error, 95% confidence interval]",
            "outcomes": "[0.0637, 0.0815, (-0.1736, 0.0980)]"
        },
        {
            "subject": {
                "analysis": "meta-regression",
                "covariate": "Female proportion",
                "statistical representation": "95% confidence interval"
            },
            "measures": "[estimate, standard error, 95% confidence interval]",
            "outcomes": "[-0.5305, 1.4575, (-3.6792, 2.6183)]"
        }
    ],
    "PMC4794224_2": [
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR2DL1",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[966, 97%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR2DL3",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[719, 72%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR2DL4",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[993, 100%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR2DL5",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[547, 55%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR2DL2*004",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[31, 3%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR2DL2*001/2/3/5",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[544, 55%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR2DP1",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[964, 97%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR2DS1",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[548, 55%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR2DS2",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[581, 59%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR2DS3",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[401, 40%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR2DS4",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[993, 100%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR2DS5",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[281, 28%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR3DL1",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[929, 94%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR3DL2",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[993, 100%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR3DL3",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[993, 100%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "KIR genotype": "KIR3DS1",
                "technique": "frequency analysis",
                "statistical representation": "N (% Positive)"
            },
            "measures": "[frequency, percentage]",
            "outcomes": "[354, 36%]"
        }
    ],
    "PMC9077443_2": [
        {
            "subject": {
                "study design": "ITT analysis",
                "analysis type": "cabotegravir effectiveness",
                "group": "cabotegravir",
                "comparison to": "TDF-FTC",
                "events": "4",
                "total person-years": "1956",
                "HIV incidence": "0.20 per 100 person-years",
                "95% CI": "0.06-0.52"
            },
            "measures": "[HIV incidence, HR]",
            "outcomes": "[0.20, 0.12]"
        },
        {
            "subject": {
                "study design": "ITT analysis",
                "analysis type": "cabotegravir effectiveness",
                "group": "TDF-FTC",
                "comparison to": "cabotegravir",
                "events": "36",
                "total person-years": "1942",
                "HIV incidence": "1.85 per 100 person-years",
                "95% CI": "1.3-2.57"
            },
            "measures": "[HIV incidence, HR]",
            "outcomes": "[1.85, 0.12]"
        },
        {
            "subject": {
                "study design": "ITT analysis",
                "analysis type": "cabotegravir effectiveness",
                "subgroup": "overall",
                "group": "TDF-FTC",
                "events": "36",
                "total person-years": "1942",
                "HIV incidence": "1.85%"
            },
            "measures": "[HIV incidence, HR]",
            "outcomes": "[0.20, 0.12]"
        },
        {
            "subject": {
                "study design": "ITT analysis",
                "analysis type": "cabotegravir effectiveness",
                "subgroup": "age",
                "sub-subgroup": "<25 years",
                "group": "TDF-FTC",
                "events": "20",
                "total person-years": "851",
                "HIV incidence": "2.34%"
            },
            "measures": "[HIV incidence, HR]",
            "outcomes": "[0.35, 0.17]"
        },
        {
            "subject": {
                "study design": "ITT analysis",
                "analysis type": "cabotegravir effectiveness",
                "subgroup": "age",
                "sub-subgroup": "\u226525 years",
                "group": "TDF-FTC",
                "events": "16",
                "total person-years": "1091",
                "HIV incidence": "1.47%"
            },
            "measures": "[HIV incidence, HR]",
            "outcomes": "[0.09, 0.09]"
        },
        {
            "subject": {
                "study design": "ITT analysis",
                "analysis type": "cabotegravir effectiveness",
                "subgroup": "contraceptive method",
                "sub-subgroup": "DMPA",
                "group": "TDF-FTC",
                "events": "21",
                "total person-years": "1000",
                "HIV incidence": "2.10%"
            },
            "measures": "[HIV incidence, HR]",
            "outcomes": "[0.30, 0.16]"
        },
        {
            "subject": {
                "study design": "ITT analysis",
                "analysis type": "cabotegravir effectiveness",
                "subgroup": "contraceptive method",
                "sub-subgroup": "NET-EN",
                "group": "TDF-FTC",
                "events": "6",
                "total person-years": "182",
                "HIV incidence": "3.30%"
            },
            "measures": "[HIV incidence, HR]",
            "outcomes": "[0.57, 0.22]"
        },
        {
            "subject": {
                "study design": "ITT analysis",
                "analysis type": "cabotegravir effectiveness",
                "subgroup": "contraceptive method",
                "sub-subgroup": "Implant",
                "group": "TDF-FTC",
                "events": "8",
                "total person-years": "607",
                "HIV incidence": "1.32%"
            },
            "measures": "[HIV incidence, HR]",
            "outcomes": "[., 0.06]"
        },
        {
            "subject": {
                "study design": "ITT analysis",
                "analysis type": "cabotegravir effectiveness",
                "subgroup": "contraceptive method",
                "sub-subgroup": "Other",
                "group": "TDF-FTC",
                "events": "1",
                "total person-years": "152",
                "HIV incidence": "0.66%"
            },
            "measures": "[HIV incidence, HR]",
            "outcomes": "[., 0.32]"
        },
        {
            "subject": {
                "study design": "ITT analysis",
                "analysis type": "cabotegravir effectiveness",
                "subgroup": "body-mass index",
                "sub-subgroup": "\u226430 kg/m\u00b2",
                "group": "TDF-FTC",
                "events": "27",
                "total person-years": "1447",
                "HIV incidence": "1.87%"
            },
            "measures": "[HIV incidence, HR]",
            "outcomes": "[0.29, 0.16]"
        },
        {
            "subject": {
                "study design": "ITT analysis",
                "analysis type": "cabotegravir effectiveness",
                "subgroup": "body-mass index",
                "sub-subgroup": ">30 kg/m\u00b2",
                "group": "TDF-FTC",
                "events": "9",
                "total person-years": "495",
                "HIV incidence": "1.82%"
            },
            "measures": "[HIV incidence, HR]",
            "outcomes": "[., 0.05]"
        }
    ],
    "PMC10294491_2": [
        {
            "subject": {
                "trial": "DISCOVER",
                "analysis": "primary outcome analysis",
                "group": "TDF/FTC",
                "no. subjects": "2693",
                "PYFU": "4386",
                "incident HIV infections": "11",
                "incidence rate": "0.251 per 100 PYFU",
                "rate ratio": "REF"
            },
            "measures": "[incidence rate, rate ratio]",
            "outcomes": "[0.251 per 100 PYFU, REF]"
        },
        {
            "subject": {
                "trial": "DISCOVER",
                "analysis": "primary outcome analysis",
                "group": "TAF/FTC",
                "no. subjects": "2694",
                "PYFU": "4370",
                "incident HIV infections": "6",
                "incidence rate": "0.137 per 100 PYFU",
                "rate ratio": "0.55 (0.20, 1.48)"
            },
            "measures": "[incidence rate, rate ratio]",
            "outcomes": "[0.137 per 100 PYFU, 0.55 (0.20, 1.48)]"
        },
        {
            "subject": {
                "trial": "DISCOVER",
                "analysis": "re-analysis using an averted infections framework",
                "group": "TDF/FTC",
                "PYFU": "4386",
                "observed infections": "11",
                "predicted infections": "90.4",
                "averted infections": "79.4",
                "averted infections ratio": "REF"
            },
            "measures": "[averted infections, averted infections ratio]",
            "outcomes": "[79.4, REF]"
        },
        {
            "subject": {
                "trial": "DISCOVER",
                "analysis": "re-analysis using an averted infections framework",
                "group": "TAF/FTC",
                "PYFU": "4370",
                "observed infections": "6",
                "predicted infections": "90.0",
                "averted infections": "84.0",
                "averted infections ratio": "1.06 (0.96\u20131.17)"
            },
            "measures": "[averted infections, averted infections ratio]",
            "outcomes": "[84.0, 1.06 (0.96\u20131.17)]"
        },
        {
            "subject": {
                "counterfactual placebo incidence rate": "2.06 per 100 PYFU",
                "credibility limit": "lower 2.5%"
            },
            "measures": "[]",
            "outcomes": "[]"
        }
    ],
    "PMC6158807_3": [
        {
            "subject": {
                "study type": "incidence rates of non-AIDS composite events",
                "endpoint": "composite endpoint",
                "number of patients": "692",
                "statistical test": "long rank test",
                "p value": "< 0.001"
            },
            "measures": "[number of events, person-year of follow-up, rate per 100 person-year, 95% CI]",
            "outcomes": "[123, 4071, 3.02, 2.53\u20133.61]"
        },
        {
            "subject": {
                "study type": "incidence rates of non-AIDS composite events",
                "endpoint": "composite endpoint",
                "CD4/CD8 ratio": "< 0.3",
                "statistical test": "long rank test",
                "p value": "< 0.001"
            },
            "measures": "[number of events, person-year of follow-up, rate per 100 person-year, 95% CI]",
            "outcomes": "[21, 184, 11.42, 7.45\u201317.52]"
        },
        {
            "subject": {
                "study type": "incidence rates of non-AIDS composite events",
                "endpoint": "composite endpoint",
                "CD4/CD8 ratio": "0.30\u20130.45",
                "statistical test": "long rank test",
                "p value": "< 0.001"
            },
            "measures": "[number of events, person-year of follow-up, rate per 100 person-year, 95% CI]",
            "outcomes": "[28, 496, 5.64, 3.90\u20138.17]"
        },
        {
            "subject": {
                "study type": "incidence rates of non-AIDS composite events",
                "endpoint": "composite endpoint",
                "CD4/CD8 ratio": "> 0.45",
                "statistical test": "long rank test",
                "p value": "< 0.001"
            },
            "measures": "[number of events, person-year of follow-up, rate per 100 person-year, 95% CI]",
            "outcomes": "[72, 3227, 2.23, 1.77\u20132.81]"
        }
    ],
    "PMC7522205_2": [
        {
            "subject": {
                "study type": "observational",
                "patient population": "newly diagnosed HIV patients",
                "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                "HIV-1 genotype": "Total",
                "patients": "2845 (100.0)",
                "CD4+ median (IQR)": "160 (49\u2013310)"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "observational",
                "patient population": "newly diagnosed HIV patients",
                "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                "HIV-1 genotype": "CRF01_AE",
                "patients": "1687 (59.3)",
                "CD4+ median (IQR)": "111 (31\u2013279)"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study type": "observational",
                "patient population": "newly diagnosed HIV patients",
                "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                "HIV-1 genotype": "CRF07_BC",
                "patients": "254 (8.9)",
                "CD4+ median (IQR)": "250 (156\u2013377)"
            },
            "measures": "[unadjusted coefficient, adjusted coefficient]",
            "outcomes": "[139 (117\u2013161), <0.001, 113 (86\u2013140), <0.001]"
        },
        {
            "subject": {
                "study type": "observational",
                "patient population": "newly diagnosed HIV patients",
                "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                "HIV-1 genotype": "CRF08_BC",
                "patients": "728 (25.6)",
                "CD4+ median (IQR)": "205 (108\u2013327)"
            },
            "measures": "[unadjusted coefficient, adjusted coefficient]",
            "outcomes": "[94 (73\u2013115), <0.001, 80 (65\u201395), <0.001]"
        },
        {
            "subject": {
                "study type": "observational",
                "patient population": "newly diagnosed HIV patients",
                "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                "HIV-1 genotype": "Others",
                "patients": "176 (6.2)",
                "CD4+ median (IQR)": "198 (89\u2013355)"
            },
            "measures": "[unadjusted coefficient, adjusted coefficient]",
            "outcomes": "[87 (46\u2013128), <0.001, 72 (37\u2013107), <0.001]"
        }
    ],
    "PMC7414801_2": [
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "As-randomized",
                "n": "382"
            },
            "measures": "[HIV detection visit, HIV VL]",
            "outcomes": "[381 (100), 100]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "As-randomized",
                "n": "382"
            },
            "measures": "[M3, HIV VL]",
            "outcomes": "[114 (30), 30]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "As-randomized",
                "n": "382"
            },
            "measures": "[M6, HIV VL]",
            "outcomes": "[73 (19), 19]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "As-randomized",
                "n": "382"
            },
            "measures": "[M9, HIV VL]",
            "outcomes": "[43 (11), 11]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "As-randomized",
                "n": "382"
            },
            "measures": "[M12, HIV VL]",
            "outcomes": "[26 (7), 7]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "As-randomized",
                "n": "382"
            },
            "measures": "[M15, HIV VL]",
            "outcomes": "[17 (4), 4]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "As-randomized",
                "n": "382"
            },
            "measures": "[HIV detection visit, CD4]",
            "outcomes": "[382 (100), 100]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "As-randomized",
                "n": "382"
            },
            "measures": "[M3, CD4]",
            "outcomes": "[115 (30), 30]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "As-randomized",
                "n": "382"
            },
            "measures": "[M6, CD4]",
            "outcomes": "[73 (19), 19]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "As-randomized",
                "n": "382"
            },
            "measures": "[M9, CD4]",
            "outcomes": "[44 (12), 12]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "As-randomized",
                "n": "382"
            },
            "measures": "[M12, CD4]",
            "outcomes": "[26 (7), 7]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "As-randomized",
                "n": "382"
            },
            "measures": "[M15, CD4]",
            "outcomes": "[17 (4), 4]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "Continuous use",
                "n": "331"
            },
            "measures": "[HIV detection visit, HIV VL]",
            "outcomes": "[330 (100), 100]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "Continuous use",
                "n": "331"
            },
            "measures": "[M3, HIV VL]",
            "outcomes": "[99 (30), 30]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "Continuous use",
                "n": "331"
            },
            "measures": "[M6, HIV VL]",
            "outcomes": "[65 (20), 20]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "Continuous use",
                "n": "331"
            },
            "measures": "[M9, HIV VL]",
            "outcomes": "[40 (12), 12]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "Continuous use",
                "n": "331"
            },
            "measures": "[M12, HIV VL]",
            "outcomes": "[25 (8), 8]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "Continuous use",
                "n": "331"
            },
            "measures": "[M15, HIV VL]",
            "outcomes": "[14 (4), 4]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "Continuous use",
                "n": "331"
            },
            "measures": "[HIV detection visit, CD4]",
            "outcomes": "[331 (100), 100]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "Continuous use",
                "n": "331"
            },
            "measures": "[M3, CD4]",
            "outcomes": "[99 (30), 30]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "Continuous use",
                "n": "331"
            },
            "measures": "[M6, CD4]",
            "outcomes": "[64 (19), 19]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "Continuous use",
                "n": "331"
            },
            "measures": "[M9, CD4]",
            "outcomes": "[40 (12), 12]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "Continuous use",
                "n": "331"
            },
            "measures": "[M12, CD4]",
            "outcomes": "[25 (8), 8]"
        },
        {
            "subject": {
                "study type": "HIV Seroconverter",
                "analysis": "Summary of HIV Seroconverter Data",
                "data type": "Available by Months Since HIV Detection Visit",
                "exclusion criteria": "women infected at baseline and visits following ART initiation",
                "group": "Continuous use",
                "n": "331"
            },
            "measures": "[M15, CD4]",
            "outcomes": "[14 (4), 4]"
        }
    ],
    "PMC11437459_2": [
        {
            "subject": {
                "treatment": "Combination therapies for the treatment of HIV",
                "combination": "Atripla",
                "approval date": "2006",
                "TDF": "+",
                "TAF": "-",
                "Emtricitabine (FTC)": "+",
                "Efavirenz (EFV)": "+",
                "Rilpivirine (RPV)": "-",
                "Dolutegravir (DTG)": "-",
                "Elvitegravir (EVG)": "-",
                "Cobicistat (COBI)": "-",
                "Abacavir (ABC)": "-",
                "Lamivudine (3TC)": "-"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "treatment": "Combination therapies for the treatment of HIV",
                "combination": "Complera",
                "approval date": "2011",
                "TDF": "+",
                "TAF": "-",
                "Emtricitabine (FTC)": "+",
                "Efavirenz (EFV)": "-",
                "Rilpivirine (RPV)": "+",
                "Dolutegravir (DTG)": "-",
                "Elvitegravir (EVG)": "-",
                "Cobicistat (COBI)": "-",
                "Abacavir (ABC)": "-",
                "Lamivudine (3TC)": "-"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "treatment": "Combination therapies for the treatment of HIV",
                "combination": "Odefsey",
                "approval date": "2016",
                "TDF": "-",
                "TAF": "+",
                "Emtricitabine (FTC)": "+",
                "Efavirenz (EFV)": "-",
                "Rilpivirine (RPV)": "+",
                "Dolutegravir (DTG)": "-",
                "Elvitegravir (EVG)": "-",
                "Cobicistat (COBI)": "-",
                "Abacavir (ABC)": "-",
                "Lamivudine (3TC)": "-"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "treatment": "Combination therapies for the treatment of HIV",
                "combination": "Stribild",
                "approval date": "2012",
                "TDF": "+",
                "TAF": "-",
                "Emtricitabine (FTC)": "+",
                "Efavirenz (EFV)": "-",
                "Rilpivirine (RPV)": "-",
                "Dolutegravir (DTG)": "-",
                "Elvitegravir (EVG)": "+",
                "Cobicistat (COBI)": "+",
                "Abacavir (ABC)": "-",
                "Lamivudine (3TC)": "-"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "treatment": "Combination therapies for the treatment of HIV",
                "combination": "Genvoya",
                "approval date": "2015",
                "TDF": "-",
                "TAF": "+",
                "Emtricitabine (FTC)": "+",
                "Efavirenz (EFV)": "-",
                "Rilpivirine (RPV)": "-",
                "Dolutegravir (DTG)": "-",
                "Elvitegravir (EVG)": "+",
                "Cobicistat (COBI)": "+",
                "Abacavir (ABC)": "-",
                "Lamivudine (3TC)": "-"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "treatment": "Combination therapies for the treatment of HIV",
                "combination": "Triumeq",
                "approval date": "2014",
                "TDF": "-",
                "TAF": "-",
                "Emtricitabine (FTC)": "-",
                "Efavirenz (EFV)": "-",
                "Rilpivirine (RPV)": "-",
                "Dolutegravir (DTG)": "+",
                "Elvitegravir (EVG)": "-",
                "Cobicistat (COBI)": "-",
                "Abacavir (ABC)": "+",
                "Lamivudine (3TC)": "+"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "treatment": "Combination therapies for the treatment of HIV",
                "combination": "Dovato",
                "approval date": "2019",
                "TDF": "-",
                "TAF": "-",
                "Emtricitabine (FTC)": "-",
                "Efavirenz (EFV)": "-",
                "Rilpivirine (RPV)": "-",
                "Dolutegravir (DTG)": "+",
                "Elvitegravir (EVG)": "-",
                "Cobicistat (COBI)": "-",
                "Abacavir (ABC)": "-",
                "Lamivudine (3TC)": "+"
            },
            "measures": "[]",
            "outcomes": "[]"
        }
    ],
    "PMC9624454_2": [
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "total number": "1024"
            },
            "measures": "[CMV viremia, P Value]",
            "outcomes": "[314 (30.7), -]"
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "HIV exposure": "all children"
            },
            "measures": "[CMV viremia \u2264 1000 IU/mL, P Value]",
            "outcomes": "[59 (5.8), -]"
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "HIV exposure": "all children"
            },
            "measures": "[log10 CMV IU/mL in Viremics, P Value]",
            "outcomes": "[2.3 (1.9\u20132.7), -]"
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "HIV exposure": "HIV unexposed"
            },
            "measures": "[CMV viremia, P Value]",
            "outcomes": "[253 (29.0), -]"
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "HIV exposure": "HIV unexposed"
            },
            "measures": "[CMV viremia \u2264 1000 IU/mL, P Value]",
            "outcomes": "[45 (5.2), -]"
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "HIV exposure": "HIV unexposed"
            },
            "measures": "[log10 CMV IU/mL in Viremics, P Value]",
            "outcomes": "[2.3 (1.9\u20132.7), -]"
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "HIV exposure": "HIV exposed"
            },
            "measures": "[CMV viremia, P Value]",
            "outcomes": "[45 (38.1), 0.061]"
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "HIV exposure": "HIV exposed"
            },
            "measures": "[CMV viremia \u2264 1000 IU/mL, P Value]",
            "outcomes": "[10 (8.5), 0.18]"
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "HIV exposure": "HIV exposed"
            },
            "measures": "[log10 CMV IU/mL in Viremics, P Value]",
            "outcomes": "[2.4 (2.0\u20132.9), 0.24]"
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "HIV exposure": "HIV exposed uninfected"
            },
            "measures": "[CMV viremia, P Value]",
            "outcomes": "[36 (37.1), 0.088]"
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "HIV exposure": "HIV exposed uninfected"
            },
            "measures": "[CMV viremia \u2264 1000 IU/mL, P Value]",
            "outcomes": "[6 (6.2), 0.56]"
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "HIV exposure": "HIV exposed uninfected"
            },
            "measures": "[log10 CMV IU/mL in Viremics, P Value]",
            "outcomes": "[2.4 (1.9\u20132.7), 0.74]"
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "HIV exposure": "HIV infected"
            },
            "measures": "[CMV viremia, P Value]",
            "outcomes": "[6 (40.0), 0.39]"
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "HIV exposure": "HIV infected"
            },
            "measures": "[CMV viremia \u2264 1000 IU/mL, P Value]",
            "outcomes": "[3 (20.0), 0.015]"
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "analysis": "CMV detection, high-level viremia, and median viral loads",
                "stratification": "HIV exposure or infection",
                "HIV exposure": "HIV infected"
            },
            "measures": "[log10 CMV IU/mL in Viremics, P Value]",
            "outcomes": "[3.2 (2.6\u20135.3), 0.012]"
        }
    ],
    "PMC4549947_4": [
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "executive function",
                "group": "Females",
                "statistical representation": "OR (95% CI)"
            },
            "measures": "[effect size, P]",
            "outcomes": "[1.3, NA]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "executive function",
                "group": "Males",
                "statistical representation": "OR (95% CI)"
            },
            "measures": "[effect size, P]",
            "outcomes": "[3.5, 0.008]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "executive function",
                "group": "Hispanics",
                "statistical representation": "OR"
            },
            "measures": "[effect size, NA]",
            "outcomes": "[2.6, NA]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "executive function",
                "group": "African American",
                "statistical representation": "OR (95% CI)"
            },
            "measures": "[effect size, P]",
            "outcomes": "[3.1, 0.01]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "executive function",
                "group": "Alcohol use",
                "statistical representation": "OR"
            },
            "measures": "[effect size, NA]",
            "outcomes": "[2.6, NA]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "executive function",
                "group": "Females and Males",
                "statistical representation": "p interaction"
            },
            "measures": "[interaction P, NA]",
            "outcomes": "[0.35, NA]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "executive function",
                "group": "Hispanics and African American",
                "statistical representation": "p interaction"
            },
            "measures": "[interaction P, NA]",
            "outcomes": "[0.05, NA]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "cognitive flexibility",
                "group": "Females",
                "statistical representation": "OR"
            },
            "measures": "[effect size, NA]",
            "outcomes": "[0.9, NA]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "cognitive flexibility",
                "group": "Males",
                "statistical representation": "OR (95% CI)"
            },
            "measures": "[effect size, P]",
            "outcomes": "[1.8, 0.01]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "cognitive flexibility",
                "group": "Hispanics",
                "statistical representation": "OR"
            },
            "measures": "[effect size, NA]",
            "outcomes": "[1.9, NA]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "cognitive flexibility",
                "group": "African American",
                "statistical representation": "OR"
            },
            "measures": "[effect size, NA]",
            "outcomes": "[1.5, NA]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "cognitive flexibility",
                "group": "Alcohol use",
                "statistical representation": "OR (95% CI)"
            },
            "measures": "[effect size, P]",
            "outcomes": "[1.6, 0.03]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "cognitive flexibility",
                "group": "Females and Males",
                "statistical representation": "p interaction"
            },
            "measures": "[interaction P, NA]",
            "outcomes": "[0.013, NA]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "cognitive flexibility",
                "group": "Hispanics and African American",
                "statistical representation": "p interaction"
            },
            "measures": "[interaction P, NA]",
            "outcomes": "[0.72, NA]"
        },
        {
            "subject": {
                "analysis": "DRD2 associations with cognitive flexibility and executive function",
                "gene": "DRD2",
                "variant": "rs6277",
                "trait": "cognitive flexibility",
                "group": "Alcohol use",
                "statistical representation": "p interaction"
            },
            "measures": "[interaction P, NA]",
            "outcomes": "[0.32, NA]"
        }
    ],
    "PMC6694514_3": [
        {
            "subject": {
                "study": "REMoxTB trial",
                "adverse event type": "Hepatobiliary disorders",
                "HIV status": "HIV-positive",
                "grade": "3 or 4",
                "event frequency": "12",
                "percentage of total G3+ events": "30.0%"
            },
            "measures": "[adverse event frequency, percentage of total G3+ events]",
            "outcomes": "[12, 30.0%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "adverse event type": "Hepatobiliary disorders",
                "HIV status": "HIV-negative",
                "grade": "3 or 4",
                "event frequency": "15",
                "percentage of total G3+ events": "25.0%"
            },
            "measures": "[adverse event frequency, percentage of total G3+ events]",
            "outcomes": "[15, 25.0%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "adverse event type": "Respiratory and thoracic disorders",
                "HIV status": "HIV-positive",
                "grade": "3 or 4",
                "event frequency": "7",
                "percentage of total G3+ events": "17.5%"
            },
            "measures": "[adverse event frequency, percentage of total G3+ events]",
            "outcomes": "[7, 17.5%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "adverse event type": "Respiratory and thoracic disorders",
                "HIV status": "HIV-negative",
                "grade": "3 or 4",
                "event frequency": "13",
                "percentage of total G3+ events": "21.7%"
            },
            "measures": "[adverse event frequency, percentage of total G3+ events]",
            "outcomes": "[13, 21.7%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "adverse event type": "Blood and lymphatic disorders",
                "HIV status": "HIV-positive",
                "grade": "3 or 4",
                "event frequency": "6",
                "percentage of total G3+ events": "15.0%"
            },
            "measures": "[adverse event frequency, percentage of total G3+ events]",
            "outcomes": "[6, 15.0%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "adverse event type": "Blood and lymphatic disorders",
                "HIV status": "HIV-negative",
                "grade": "3 or 4",
                "event frequency": "10",
                "percentage of total G3+ events": "16.7%"
            },
            "measures": "[adverse event frequency, percentage of total G3+ events]",
            "outcomes": "[10, 16.7%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "adverse event type": "Infections and infestations",
                "HIV status": "HIV-positive",
                "grade": "3 or 4",
                "event frequency": "3",
                "percentage of total G3+ events": "7.5%"
            },
            "measures": "[adverse event frequency, percentage of total G3+ events]",
            "outcomes": "[3, 7.5%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "adverse event type": "Infections and infestations",
                "HIV status": "HIV-negative",
                "grade": "3 or 4",
                "event frequency": "5",
                "percentage of total G3+ events": "8.3%"
            },
            "measures": "[adverse event frequency, percentage of total G3+ events]",
            "outcomes": "[5, 8.3%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "adverse event type": "Metabolism and nutrition disorders",
                "HIV status": "HIV-positive",
                "grade": "3 or 4",
                "event frequency": "3",
                "percentage of total G3+ events": "7.5%"
            },
            "measures": "[adverse event frequency, percentage of total G3+ events]",
            "outcomes": "[3, 7.5%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "adverse event type": "Metabolism and nutrition disorders",
                "HIV status": "HIV-negative",
                "grade": "3 or 4",
                "event frequency": "4",
                "percentage of total G3+ events": "6.7%"
            },
            "measures": "[adverse event frequency, percentage of total G3+ events]",
            "outcomes": "[4, 6.7%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "adverse event type": "Other",
                "HIV status": "HIV-positive",
                "grade": "3 or 4",
                "event frequency": "9",
                "percentage of total G3+ events": "17.5%"
            },
            "measures": "[adverse event frequency, percentage of total G3+ events]",
            "outcomes": "[9, 17.5%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "adverse event type": "Other",
                "HIV status": "HIV-negative",
                "grade": "3 or 4",
                "event frequency": "13",
                "percentage of total G3+ events": "16.7%"
            },
            "measures": "[adverse event frequency, percentage of total G3+ events]",
            "outcomes": "[13, 16.7%]"
        }
    ],
    "PMC6937831_2": [
        {
            "subject": {
                "category": "Death category of individuals living with HIV",
                "death type": "Non-AIDS-Related Death (NARD)",
                "cause": "Cancer",
                "number of deaths": "6",
                "percentage": "4%"
            },
            "measures": "[number of deaths, percentage]",
            "outcomes": "[6, 4%]"
        },
        {
            "subject": {
                "category": "Death category of individuals living with HIV",
                "death type": "Non-AIDS-Related Death (NARD)",
                "cause": "Other diseases",
                "number of deaths": "10",
                "percentage": "8%"
            },
            "measures": "[number of deaths, percentage]",
            "outcomes": "[10, 8%]"
        },
        {
            "subject": {
                "category": "Death category of individuals living with HIV",
                "death type": "Non-AIDS-Related Death (NARD)",
                "cause": "CVD",
                "number of deaths": "12",
                "percentage": "9%"
            },
            "measures": "[number of deaths, percentage]",
            "outcomes": "[12, 9%]"
        },
        {
            "subject": {
                "category": "Death category of individuals living with HIV",
                "death type": "Non-AIDS-Related Death (NARD)",
                "cause": "Hepatic/liver-related",
                "number of deaths": "34",
                "percentage": "24%"
            },
            "measures": "[number of deaths, percentage]",
            "outcomes": "[34, 24%]"
        },
        {
            "subject": {
                "category": "Death category of individuals living with HIV",
                "death type": "Non-AIDS-Related Death (NARD)",
                "cause": "External death",
                "number of deaths": "78",
                "percentage": "55%"
            },
            "measures": "[number of deaths, percentage]",
            "outcomes": "[78, 55%]"
        },
        {
            "subject": {
                "category": "Death category of individuals living with HIV",
                "death type": "AIDS-Related Death (ARD)",
                "cause": "Other diseases",
                "number of deaths": "2",
                "percentage": "1%"
            },
            "measures": "[number of deaths, percentage]",
            "outcomes": "[2, 1%]"
        },
        {
            "subject": {
                "category": "Death category of individuals living with HIV",
                "death type": "AIDS-Related Death (ARD)",
                "cause": "Cancer",
                "number of deaths": "8",
                "percentage": "3%"
            },
            "measures": "[number of deaths, percentage]",
            "outcomes": "[8, 3%]"
        },
        {
            "subject": {
                "category": "Death category of individuals living with HIV",
                "death type": "AIDS-Related Death (ARD)",
                "cause": "Opportunistic",
                "number of deaths": "241",
                "percentage": "96%"
            },
            "measures": "[number of deaths, percentage]",
            "outcomes": "[241, 96%]"
        },
        {
            "subject": {
                "category": "Death category of individuals living with HIV",
                "death type": "External death",
                "description": "Sudden death, including accident, overdose, and suicide"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "category": "Death category of individuals living with HIV",
                "death type": "Other diseases",
                "description": "Unknown death categorized based on CD4 count within 6-months prior to the date of death"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "category": "Death category of individuals living with HIV",
                "death type": "Cancer",
                "description": "Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
            },
            "measures": "[]",
            "outcomes": "[]"
        }
    ],
    "PMC6949311_1": [
        {
            "subject": {
                "study": "this study",
                "group": "HIV-1/AIDS patients",
                "number": "500",
                "demographic data": "Number"
            },
            "measures": "[N]",
            "outcomes": "[500]"
        },
        {
            "subject": {
                "study": "this study",
                "group": "Healthy controls",
                "number": "500",
                "demographic data": "Number"
            },
            "measures": "[N]",
            "outcomes": "[500]"
        },
        {
            "subject": {
                "study": "this study",
                "group": "HIV-1/AIDS patients",
                "demographic data": "Gender",
                "gender": "Male"
            },
            "measures": "[percentage]",
            "outcomes": "[65.2%]"
        },
        {
            "subject": {
                "study": "this study",
                "group": "Healthy controls",
                "demographic data": "Gender",
                "gender": "Male"
            },
            "measures": "[percentage]",
            "outcomes": "[63.4%]"
        },
        {
            "subject": {
                "study": "this study",
                "group": "HIV-1/AIDS patients",
                "demographic data": "Gender",
                "gender": "Female"
            },
            "measures": "[percentage]",
            "outcomes": "[34.8%]"
        },
        {
            "subject": {
                "study": "this study",
                "group": "Healthy controls",
                "demographic data": "Gender",
                "gender": "Female"
            },
            "measures": "[percentage]",
            "outcomes": "[36.6%]"
        },
        {
            "subject": {
                "study": "this study",
                "group": "HIV-1/AIDS patients",
                "demographic data": "Mean age",
                "statistical representation": "mean +- SD"
            },
            "measures": "[age in years]",
            "outcomes": "[35.4 \u00b1 7.9]"
        },
        {
            "subject": {
                "study": "this study",
                "group": "Healthy controls",
                "demographic data": "Mean age",
                "statistical representation": "mean +- SD"
            },
            "measures": "[age in years]",
            "outcomes": "[36.2 \u00b1 9.8]"
        },
        {
            "subject": {
                "study": "this study",
                "group": "Healthy controls",
                "demographic data": "Gender",
                "gender": "Male"
            },
            "measures": "[P]",
            "outcomes": "[0.553]"
        },
        {
            "subject": {
                "study": "this study",
                "group": "Healthy controls",
                "demographic data": "Mean age",
                "statistical representation": "mean +- SD"
            },
            "measures": "[P]",
            "outcomes": "[0.180]"
        }
    ],
    "PMC8340029_2": [
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "on-site",
                "time period": "before access",
                "analysis": "incidence",
                "statistical representation": "rate",
                "unit": "person-years",
                "number of infections": "133",
                "person-years": "2860",
                "incidence": "4.65%"
            },
            "measures": "[incidence]",
            "outcomes": "[4.65%]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "on-site",
                "time period": "after access",
                "analysis": "incidence",
                "statistical representation": "rate",
                "unit": "person-years",
                "number of infections": "12",
                "person-years": "556",
                "incidence": "2.16%"
            },
            "measures": "[incidence]",
            "outcomes": "[2.16%]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "on-site",
                "time period": "after access",
                "analysis": "incidence rate ratio",
                "statistical representation": "rate ratio (95% CI)",
                "adjusted for": "study site and randomisation group",
                "incidence rate ratio": "0.45 (0.25-0.81)",
                "p value": "0.0076"
            },
            "measures": "[incidence rate ratio, p value]",
            "outcomes": "[0.45 (0.25-0.81), 0.0076]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "on-site",
                "time period": "after access",
                "analysis": "incidence rate ratio",
                "statistical representation": "rate ratio (95% CI)",
                "adjusted for": "study site and randomisation group",
                "incidence rate ratio": "0.45 (0.25-0.82)",
                "p value": "0.0085"
            },
            "measures": "[incidence rate ratio, p value]",
            "outcomes": "[0.45 (0.25-0.82), 0.0085]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "on-site",
                "time period": "before access",
                "analysis": "incidence",
                "statistical representation": "rate",
                "unit": "person-years",
                "number of infections": "46",
                "person-years": "919",
                "incidence": "5.00%"
            },
            "measures": "[incidence]",
            "outcomes": "[5.00%]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "on-site",
                "time period": "after access",
                "analysis": "incidence",
                "statistical representation": "rate",
                "unit": "person-years",
                "number of infections": "11",
                "person-years": "481",
                "incidence": "2.29%"
            },
            "measures": "[incidence]",
            "outcomes": "[2.29%]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "on-site",
                "time period": "after access",
                "analysis": "incidence rate ratio",
                "statistical representation": "rate ratio (95% CI)",
                "adjusted for": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)",
                "incidence rate ratio": "0.44 (0.23-0.85)",
                "p value": "0.015"
            },
            "measures": "[incidence rate ratio, p value]",
            "outcomes": "[0.44 (0.23-0.85), 0.015]"
        },
        {
            "subject": {
                "study design": "observational",
                "PrEP access": "on-site",
                "time period": "after access",
                "analysis": "incidence rate ratio",
                "statistical representation": "rate ratio (95% CI)",
                "adjusted for": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)",
                "incidence rate ratio": "0.43 (0.22-0.83)",
                "p value": "0.012"
            },
            "measures": "[incidence rate ratio, p value]",
            "outcomes": "[0.43 (0.22-0.83), 0.012]"
        }
    ],
    "PMC4731573_1": [
        {
            "subject": {
                "analysis": "Quantification of HIV-1 (P-24) and HIV-2 (P-26) antigens",
                "donor": "No. 1",
                "technique": "Alliance HIV-1 p24 Antigen ELISA Kit (Perkin Elmer)",
                "HIV type": "HIV-1"
            },
            "measures": "[HIV-1 p24 (pg/ml)]",
            "outcomes": "[1909]"
        },
        {
            "subject": {
                "analysis": "Quantification of HIV-1 (P-24) and HIV-2 (P-26) antigens",
                "donor": "No. 1",
                "technique": "RETRO-TEK SIV p27 Antigen ELISA Kit (ZeptoMetrix)",
                "HIV type": "HIV-2"
            },
            "measures": "[HIV-2 p26 (pg/ml)]",
            "outcomes": "[17683.965]"
        },
        {
            "subject": {
                "analysis": "Quantification of HIV-1 (P-24) and HIV-2 (P-26) antigens",
                "donor": "No. 2",
                "technique": "Alliance HIV-1 p24 Antigen ELISA Kit (Perkin Elmer)",
                "HIV type": "HIV-1"
            },
            "measures": "[HIV-1 p24 (pg/ml)]",
            "outcomes": "[5649]"
        },
        {
            "subject": {
                "analysis": "Quantification of HIV-1 (P-24) and HIV-2 (P-26) antigens",
                "donor": "No. 2",
                "technique": "RETRO-TEK SIV p27 Antigen ELISA Kit (ZeptoMetrix)",
                "HIV type": "HIV-2"
            },
            "measures": "[HIV-2 p26 (pg/ml)]",
            "outcomes": "[46071.77]"
        },
        {
            "subject": {
                "analysis": "Quantification of HIV-1 (P-24) and HIV-2 (P-26) antigens",
                "donor": "No. 3",
                "technique": "Alliance HIV-1 p24 Antigen ELISA Kit (Perkin Elmer)",
                "HIV type": "HIV-1"
            },
            "measures": "[HIV-1 p24 (pg/ml)]",
            "outcomes": "[1803]"
        },
        {
            "subject": {
                "analysis": "Quantification of HIV-1 (P-24) and HIV-2 (P-26) antigens",
                "donor": "No. 3",
                "technique": "RETRO-TEK SIV p27 Antigen ELISA Kit (ZeptoMetrix)",
                "HIV type": "HIV-2"
            },
            "measures": "[HIV-2 p26 (pg/ml)]",
            "outcomes": "[41414.58]"
        }
    ],
    "PMC9720390_1": [
        {
            "subject": {
                "study characteristic": "Number of participants",
                "PrEP dose": "One PrEP dose",
                "study design": "Characteristics of study participants by number of PrEP doses"
            },
            "measures": "[Number of participants]",
            "outcomes": "[48]"
        },
        {
            "subject": {
                "study characteristic": "Number of participants",
                "PrEP dose": "Two PrEP doses",
                "study design": "Characteristics of study participants by number of PrEP doses"
            },
            "measures": "[Number of participants]",
            "outcomes": "[48]"
        },
        {
            "subject": {
                "study characteristic": "Number of participants",
                "PrEP dose": "No PrEP",
                "study design": "Characteristics of study participants by number of PrEP doses"
            },
            "measures": "[Number of participants]",
            "outcomes": "[16]"
        },
        {
            "subject": {
                "study characteristic": "Median age (years)",
                "PrEP dose": "One PrEP dose",
                "study design": "Characteristics of study participants by number of PrEP doses"
            },
            "measures": "[Median age (years)]",
            "outcomes": "[19]"
        },
        {
            "subject": {
                "study characteristic": "Median age (years)",
                "PrEP dose": "Two PrEP doses",
                "study design": "Characteristics of study participants by number of PrEP doses"
            },
            "measures": "[Median age (years)]",
            "outcomes": "[19]"
        },
        {
            "subject": {
                "study characteristic": "Median age (years)",
                "PrEP dose": "No PrEP",
                "study design": "Characteristics of study participants by number of PrEP doses"
            },
            "measures": "[Median age (years)]",
            "outcomes": "[19]"
        },
        {
            "subject": {
                "study characteristic": "STI positivity",
                "PrEP dose": "One PrEP dose",
                "study design": "Characteristics of study participants by number of PrEP doses"
            },
            "measures": "[STI positivity]",
            "outcomes": "[2]"
        },
        {
            "subject": {
                "study characteristic": "STI positivity",
                "PrEP dose": "Two PrEP doses",
                "study design": "Characteristics of study participants by number of PrEP doses"
            },
            "measures": "[STI positivity]",
            "outcomes": "[4]"
        },
        {
            "subject": {
                "study characteristic": "STI positivity",
                "PrEP dose": "No PrEP",
                "study design": "Characteristics of study participants by number of PrEP doses"
            },
            "measures": "[STI positivity]",
            "outcomes": "[0]"
        }
    ],
    "PMC11576434_2": [
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "gene": "TRAF4",
                "gene name": "TNF receptor associated factor 4",
                "protein": "TRAF4",
                "protein function": "Adaptor protein involved in signal transduction and regulation of immune response, cell proliferation and apoptosis"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "gene": "RAP2B",
                "gene name": "RAP2B, member of RAS oncogene family",
                "protein": "RAP2B",
                "protein function": "Small GTPase involved in regulation of cell junction assembly and cell\u2013cell adhesion"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "gene": "CCND1",
                "gene name": "Cyclin D1",
                "protein": "Cyclin D1",
                "protein function": "Regulates cell cycle progression"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "gene": "NPHP4",
                "gene name": "Nephrocystin 4",
                "protein": "Nephrocystin 4",
                "protein function": "Functions in cilia and cell\u2013cell junctions; disruption leads to defects in epithelial architecture"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "gene": "TJAP1",
                "gene name": "Tight junction associated protein 1",
                "protein": "TJAP1",
                "protein function": "Scaffolding protein at tight junctions, involved in linking membrane proteins to cytoskeleton"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "gene": "ACTB",
                "gene name": "Actin beta",
                "protein": "\u03b2-actin",
                "protein function": "Structural protein involved in cell shape and motility"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "gene": "CRB3",
                "gene name": "Crumbs homolog 3",
                "protein": "CRB3",
                "protein function": "Maintains apical\u2013basal polarity in epithelial cells and tight junction integrity"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "gene": "PRKCZ",
                "gene name": "Protein kinase C zeta",
                "protein": "PKC\u03b6",
                "protein function": "Involved in TJ formation and maintenance via regulation of polarity complex proteins"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "gene": "CDH5",
                "gene name": "Cadherin 5",
                "protein": "VE-cadherin",
                "protein function": "Calcium-dependent adhesion protein involved in endothelial cell\u2013cell adhesion"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "gene": "ATP7B",
                "gene name": "ATPase copper transporting beta",
                "protein": "ATP7B",
                "protein function": "Involved in copper transport and homeostasis; linked to oxidative stress regulation in epithelial cells"
            },
            "measures": "[]",
            "outcomes": "[]"
        }
    ],
    "PMC4486388_1": [
        {
            "subject": {
                "vaccination group": "1",
                "N": "10",
                "N*": "9",
                "mode of HIV-DNA delivery": "No electroporation",
                "left arm": "1 inj 100 \u00b5l 0.3 mg DNA",
                "right arm": "1 inj 100 \u00b5l 0.3 mg DNA",
                "left arm IM immunization using needle": "1 inj HIV-MVA 10^8 pfu (1.0 ml)"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "vaccination group": "2",
                "N": "2",
                "N*": "2",
                "mode of HIV-DNA delivery": "No electroporation",
                "left arm": "1 inj 100 \u00b5l saline",
                "right arm": "1 inj 100 \u00b5l saline",
                "left arm IM immunization using needle": "1 inj 1.0 ml saline"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "vaccination group": "2",
                "N": "10",
                "N*": "7",
                "mode of HIV-DNA delivery": "Electroporation",
                "left arm": "1 inj 100 \u00b5l 0.3 mg DNA",
                "right arm": "1 inj 100 \u00b5l 0.3 mg DNA",
                "left arm IM immunization using needle": "1 inj HIV-MVA 10^8 pfu"
            },
            "measures": "[]",
            "outcomes": "[]"
        }
    ],
    "PMC8391097_3": [
        {
            "subject": {
                "study": "HIV Incidence Rate Estimates",
                "PrEP status": "Overall",
                "exclusion": "individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage",
                "HIV infections": "91",
                "total No. of individuals": "13 861",
                "total follow-up": "26 210 person-years"
            },
            "measures": "[incidence, 95% CI]",
            "outcomes": "[0.35, 0.28-0.43]"
        },
        {
            "subject": {
                "study": "HIV Incidence Rate Estimates",
                "PrEP status": "Linked but not prescribed PrEP",
                "HIV infections": "36",
                "total No. of individuals": "3013",
                "total follow-up": "4119 person-years"
            },
            "measures": "[incidence, 95% CI]",
            "outcomes": "[0.87, 0.63-1.21]"
        },
        {
            "subject": {
                "study": "HIV Incidence Rate Estimates",
                "PrEP status": "Prescribed PrEP but did not initiate",
                "HIV infections": "13",
                "total No. of individuals": "811",
                "total follow-up": "1226 person-years"
            },
            "measures": "[incidence, 95% CI]",
            "outcomes": "[1.06, 0.62-1.83]"
        },
        {
            "subject": {
                "study": "HIV Incidence Rate Estimates",
                "PrEP status": "Discontinued but reinitiated PrEP",
                "HIV infections": "4",
                "total No. of individuals": "1082",
                "total follow-up": "1420 person-years"
            },
            "measures": "[incidence, 95% CI]",
            "outcomes": "[0.28, 0.11-0.75]"
        },
        {
            "subject": {
                "study": "HIV Incidence Rate Estimates",
                "PrEP status": "Discontinued and did not reinitiate PrEP",
                "HIV infections": "38",
                "total No. of individuals": "2108",
                "total follow-up": "2973 person-years"
            },
            "measures": "[incidence, 95% CI]",
            "outcomes": "[1.28, 0.93-1.76]"
        },
        {
            "subject": {
                "study": "HIV Incidence Rate Estimates",
                "PrEP status": "Persistent on PrEP",
                "definition": "individuals who initiated and remained on PrEP throughout follow-up",
                "HIV infections": "0",
                "total No. of individuals": "5367",
                "total follow-up": "9139 person-years"
            },
            "measures": "[incidence, 95% CI]",
            "outcomes": "[0.00, 0.00-0.04]"
        }
    ],
    "PMC4358901_1": [
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "A1"
            },
            "measures": "[Number of genomes]",
            "outcomes": "[159]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "B"
            },
            "measures": "[Number of genomes]",
            "outcomes": "[1425]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "C"
            },
            "measures": "[Number of genomes]",
            "outcomes": "[554]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "D"
            },
            "measures": "[Number of genomes]",
            "outcomes": "[65]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "F1"
            },
            "measures": "[Number of genomes]",
            "outcomes": "[25]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "G"
            },
            "measures": "[Number of genomes]",
            "outcomes": "[27]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "H"
            },
            "measures": "[Number of genomes]",
            "outcomes": "[4]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "J"
            },
            "measures": "[Number of genomes]",
            "outcomes": "[2]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "K"
            },
            "measures": "[Number of genomes]",
            "outcomes": "[2]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "N",
                "subtype/CRF": "01_AE"
            },
            "measures": "[Number of genomes]",
            "outcomes": "[581]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "O",
                "subtype/CRF": "02_AG"
            },
            "measures": "[Number of genomes]",
            "outcomes": "[81]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-2",
                "dataset type": "full-length genome",
                "group": "P",
                "subtype/CRF": "A"
            },
            "measures": "[Number of genomes]",
            "outcomes": "[11]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-2",
                "dataset type": "full-length genome",
                "group": "B",
                "subtype/CRF": "B"
            },
            "measures": "[Number of genomes]",
            "outcomes": "[25]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "A1"
            },
            "measures": "[Number of patients]",
            "outcomes": "[134]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "B"
            },
            "measures": "[Number of patients]",
            "outcomes": "[657]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "C"
            },
            "measures": "[Number of patients]",
            "outcomes": "[429]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "D"
            },
            "measures": "[Number of patients]",
            "outcomes": "[57]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "F1"
            },
            "measures": "[Number of patients]",
            "outcomes": "[22]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "G"
            },
            "measures": "[Number of patients]",
            "outcomes": "[23]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "H"
            },
            "measures": "[Number of patients]",
            "outcomes": "[4]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "J"
            },
            "measures": "[Number of patients]",
            "outcomes": "[2]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "K"
            },
            "measures": "[Number of patients]",
            "outcomes": "[2]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "N",
                "subtype/CRF": "01_AE"
            },
            "measures": "[Number of patients]",
            "outcomes": "[250]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "O",
                "subtype/CRF": "02_AG"
            },
            "measures": "[Number of patients]",
            "outcomes": "[71]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-2",
                "dataset type": "full-length genome",
                "group": "P",
                "subtype/CRF": "A"
            },
            "measures": "[Number of patients]",
            "outcomes": "[9]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-2",
                "dataset type": "full-length genome",
                "group": "B",
                "subtype/CRF": "B"
            },
            "measures": "[Number of patients]",
            "outcomes": "[22]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "A1"
            },
            "measures": "[Average length in nucleotides]",
            "outcomes": "[8500]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "B"
            },
            "measures": "[Average length in nucleotides]",
            "outcomes": "[8600]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "C"
            },
            "measures": "[Average length in nucleotides]",
            "outcomes": "[8600]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "D"
            },
            "measures": "[Average length in nucleotides]",
            "outcomes": "[8500]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "F1"
            },
            "measures": "[Average length in nucleotides]",
            "outcomes": "[8500]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "G"
            },
            "measures": "[Average length in nucleotides]",
            "outcomes": "[8600]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "H"
            },
            "measures": "[Average length in nucleotides]",
            "outcomes": "[8500]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "J"
            },
            "measures": "[Average length in nucleotides]",
            "outcomes": "[8500]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "M",
                "subtype/CRF": "K"
            },
            "measures": "[Average length in nucleotides]",
            "outcomes": "[8500]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "N",
                "subtype/CRF": "01_AE"
            },
            "measures": "[Average length in nucleotides]",
            "outcomes": "[8600]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-1",
                "dataset type": "full-length genome",
                "group": "O",
                "subtype/CRF": "02_AG"
            },
            "measures": "[Average length in nucleotides]",
            "outcomes": "[8600]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-2",
                "dataset type": "full-length genome",
                "group": "P",
                "subtype/CRF": "A"
            },
            "measures": "[Average length in nucleotides]",
            "outcomes": "[8600]"
        },
        {
            "subject": {
                "study": "this study",
                "virus": "HIV-2",
                "dataset type": "full-length genome",
                "group": "B",
                "subtype/CRF": "B"
            },
            "measures": "[Average length in nucleotides]",
            "outcomes": "[8500]"
        }
    ],
    "PMC8748440_2": [
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "ISG15",
                "technique": "Cox regression",
                "statistical representation": "HR (95% CI for HR)",
                "statistical significance": "p value"
            },
            "measures": "[hazard ratio, p value]",
            "outcomes": "[0.29 (0.11\u20130.81), 0.0091]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "IFI6",
                "technique": "Cox regression",
                "statistical representation": "HR (95% CI for HR)",
                "statistical significance": "p value"
            },
            "measures": "[hazard ratio, p value]",
            "outcomes": "[0.18 (0.037\u20130.86), 0.014]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "IFI44L",
                "technique": "Cox regression",
                "statistical representation": "HR (95% CI for HR)",
                "statistical significance": "p value"
            },
            "measures": "[hazard ratio, p value]",
            "outcomes": "[0.55 (0.27\u20131.1), 0.083]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "IFI44",
                "technique": "Cox regression",
                "statistical representation": "HR (95% CI for HR)",
                "statistical significance": "p value"
            },
            "measures": "[hazard ratio, p value]",
            "outcomes": "[0.23 (0.047\u20131.2), 0.045]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "IFIT1",
                "technique": "Cox regression",
                "statistical representation": "HR (95% CI for HR)",
                "statistical significance": "p value"
            },
            "measures": "[hazard ratio, p value]",
            "outcomes": "[0.37 (0.12\u20131.1), 0.054]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "OAS3",
                "technique": "Cox regression",
                "statistical representation": "HR (95% CI for HR)",
                "statistical significance": "p value"
            },
            "measures": "[hazard ratio, p value]",
            "outcomes": "[0.52 (0.22\u20131.3), 0.15]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "XAF1",
                "technique": "Cox regression",
                "statistical representation": "HR (95% CI for HR)",
                "statistical significance": "p value"
            },
            "measures": "[hazard ratio, p value]",
            "outcomes": "[0.3 (0.1\u20130.92), 0.027]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "TRIM25",
                "technique": "Cox regression",
                "statistical representation": "HR (95% CI for HR)",
                "statistical significance": "p value"
            },
            "measures": "[hazard ratio, p value]",
            "outcomes": "[0.074 (0.0068\u20130.8), 0.023]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "CMPK2",
                "technique": "Cox regression",
                "statistical representation": "HR (95% CI for HR)",
                "statistical significance": "p value"
            },
            "measures": "[hazard ratio, p value]",
            "outcomes": "[0.23 (0.037\u20131.5), 0.074]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "RSAD2",
                "technique": "Cox regression",
                "statistical representation": "HR (95% CI for HR)",
                "statistical significance": "p value"
            },
            "measures": "[hazard ratio, p value]",
            "outcomes": "[0.2 (0.041\u20130.99), 0.032]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "EIF2AK2",
                "technique": "Cox regression",
                "statistical representation": "HR (95% CI for HR)",
                "statistical significance": "p value"
            },
            "measures": "[hazard ratio, p value]",
            "outcomes": "[0.54 (0.12\u20132.4), 0.42]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "USP18",
                "technique": "Cox regression",
                "statistical representation": "HR (95% CI for HR)",
                "statistical significance": "p value"
            },
            "measures": "[hazard ratio, p value]",
            "outcomes": "[0.23 (0.062\u20130.84), 0.022]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression for individual hub genes",
                "gene": "HERC6",
                "technique": "Cox regression",
                "statistical representation": "HR (95% CI for HR)",
                "statistical significance": "p value"
            },
            "measures": "[hazard ratio, p value]",
            "outcomes": "[0.16 (0.019\u20131.3), 0.057]"
        }
    ],
    "PMC7615197_2": [
        {
            "subject": {
                "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                "population": "Intention-to-treat population",
                "treatment": "Dexamethasone",
                "control": "Placebo",
                "number of deaths": "126/257",
                "hazard ratio": "0.85",
                "confidence interval": "0.66-1.10",
                "P value": "0.22",
                "test for proportional hazards": "0.36",
                "P-value for heterogeneity": ""
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[0.85, 0.22]"
        },
        {
            "subject": {
                "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                "population": "Intention-to-treat population",
                "treatment": "Dexamethasone",
                "control": "Placebo",
                "MRC grade": "Modified MRC grade",
                "P-value for heterogeneity": "0.63"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                "population": "Modified MRC grade: Grade I",
                "treatment": "Dexamethasone",
                "control": "Placebo",
                "number of deaths": "28/97",
                "hazard ratio": "0.72",
                "confidence interval": "0.41-1.25",
                "P value": "0.24",
                "test for proportional hazards": "0.15"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[0.72, 0.24]"
        },
        {
            "subject": {
                "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                "population": "Modified MRC grade: Grade II",
                "treatment": "Dexamethasone",
                "control": "Placebo",
                "number of deaths": "68/126",
                "hazard ratio": "0.82",
                "confidence interval": "0.58-1.16",
                "P value": "0.27",
                "test for proportional hazards": "0.57"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[0.82, 0.27]"
        },
        {
            "subject": {
                "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                "population": "Modified MRC grade: Grade III",
                "treatment": "Dexamethasone",
                "control": "Placebo",
                "number of deaths": "30/34",
                "hazard ratio": "1.11",
                "confidence interval": "0.70-1.77",
                "P value": "0.65",
                "test for proportional hazards": "0.89"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.11, 0.65]"
        }
    ],
    "PMC9008168_2": [
        {
            "subject": {
                "analysis": "incidence rates and hazard ratios of BMI \u226525 kg/m\u00b2",
                "HIV status": "without HIV",
                "ART status": "none",
                "incidence rate type": "unadjusted",
                "unit": "cases/1000 PY",
                "statistical representation": "95% CI"
            },
            "measures": "[unadjusted incidence rate, HR]",
            "outcomes": "[69.8, 1.00]"
        },
        {
            "subject": {
                "analysis": "incidence rates and hazard ratios of BMI \u226525 kg/m\u00b2",
                "HIV status": "with HIV",
                "ART status": "non-TLD ART",
                "incidence rate type": "unadjusted",
                "unit": "cases/1000 PY",
                "statistical representation": "95% CI"
            },
            "measures": "[unadjusted incidence rate, HR]",
            "outcomes": "[77.1, 1.13]"
        },
        {
            "subject": {
                "analysis": "incidence rates and hazard ratios of BMI \u226525 kg/m\u00b2",
                "HIV status": "with HIV",
                "ART status": "TLD",
                "incidence rate type": "unadjusted",
                "unit": "cases/1000 PY",
                "statistical representation": "95% CI"
            },
            "measures": "[unadjusted incidence rate, HR]",
            "outcomes": "[73.3, 1.77]"
        },
        {
            "subject": {
                "analysis": "incidence rates and hazard ratios of BMI \u226525 kg/m\u00b2",
                "HIV status": "with HIV",
                "ART status": "ART na\u00efve",
                "incidence rate type": "unadjusted",
                "unit": "cases/1000 PY",
                "statistical representation": "95% CI"
            },
            "measures": "[unadjusted incidence rate, HR]",
            "outcomes": "[37.7, 0.43]"
        }
    ],
    "PMC10022814_1": [
        {
            "subject": {
                "study design": "All-comers design",
                "primary objective": "Evaluate VE in population not on stable PrEP",
                "key secondary objectives": "Evaluate VE among those not on PrEP at acquisition"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study design": "1-Stage Run-In Design",
                "primary objective": "Evaluate VE in population declining or not adherent to PrEP at screening or after 1 stage of PrEP",
                "key secondary objectives": "Evaluate VE among those not on PrEP at acquisition, Evaluate PrEP effectiveness (PrEP vs. Placebo), Compare Vaccine vs. PrEP effectiveness"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study design": "3-Stage Run-In Design",
                "primary objective": "Evaluate VE in population declining or not adherent to PrEP at screening or after 1, 2, or 3 stages of PrEP",
                "key secondary objectives": "Evaluate VE among those not on PrEP at acquisition, Evaluate PrEP effectiveness (PrEP vs. Placebo), Compare Vaccine vs. PrEP effectiveness"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "study design": "Decliners Design",
                "primary objective": "Evaluate VE in population declining PrEP at screening",
                "key secondary objectives": "Evaluate VE among those not on PrEP at acquisition"
            },
            "measures": "[]",
            "outcomes": "[]"
        }
    ],
    "PMC7644038_3": [
        {
            "subject": {
                "analysis": "Prevalence of health outcomes",
                "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                "study design": "unadjusted",
                "health outcome": "Depression",
                "HIV status": "No HIV",
                "age": "65",
                "year": "2011\u20132016"
            },
            "measures": "[prevalence]",
            "outcomes": "[6.2%]"
        },
        {
            "subject": {
                "analysis": "Prevalence of health outcomes",
                "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                "study design": "unadjusted",
                "health outcome": "Depression",
                "HIV status": "HIV vs No HIV",
                "age": "65",
                "year": "2011\u20132016"
            },
            "measures": "[percent difference]",
            "outcomes": "[291.9%***]"
        },
        {
            "subject": {
                "analysis": "Prevalence of health outcomes",
                "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                "study design": "unadjusted",
                "health outcome": "Chronic kidney disease",
                "HIV status": "No HIV",
                "age": "65",
                "year": "2011\u20132016"
            },
            "measures": "[prevalence]",
            "outcomes": "[18.9%]"
        },
        {
            "subject": {
                "analysis": "Prevalence of health outcomes",
                "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                "study design": "unadjusted",
                "health outcome": "Chronic kidney disease",
                "HIV status": "HIV vs No HIV",
                "age": "65",
                "year": "2011\u20132016"
            },
            "measures": "[percent difference]",
            "outcomes": "[144.4%***]"
        }
    ],
    "PMC6033411_2": [
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "Age (years)",
                "age group": "15 and younger",
                "total number": "69",
                "percentage": "34.5%",
                "clustered": "22",
                "clustered percentage": "37.3%",
                "odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[1.0 (ref), \u2026]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "Age (years)",
                "age group": "16",
                "total number": "46",
                "percentage": "23%",
                "clustered": "13",
                "clustered percentage": "22%",
                "odds ratio": "0.84 (0.36\u20131.89)",
                "P-value": "0.67"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[0.84 (0.36\u20131.89), 0.67]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "Age (years)",
                "age group": "17+",
                "total number": "85",
                "percentage": "42.5%",
                "clustered": "24",
                "clustered percentage": "40.7%",
                "odds ratio": "0.87 (0.43\u20131.76)",
                "P-value": "0.69"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[0.87 (0.43\u20131.76), 0.69]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "School grade",
                "school grade": "8\u20139",
                "total number": "90",
                "percentage": "45%",
                "clustered": "30",
                "clustered percentage": "50.8%",
                "odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[1.0 (ref), \u2026]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "School grade",
                "school grade": "10\u201312",
                "total number": "110",
                "percentage": "55%",
                "clustered": "29",
                "clustered percentage": "49.2%",
                "odds ratio": "0.8 (0.43\u20131.52)",
                "P-value": "0.5"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[0.8 (0.43\u20131.52), 0.5]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "Household income (R)",
                "household income": "<999",
                "total number": "61",
                "percentage": "30.5%",
                "clustered": "22",
                "clustered percentage": "37.3%",
                "odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[1.0 (ref), \u2026]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "Household income (R)",
                "household income": "10,000\u201399,000",
                "total number": "112",
                "percentage": "56%",
                "clustered": "27",
                "clustered percentage": "45.8%",
                "odds ratio": "0.56 (0.29\u20131.11)",
                "P-value": "0.1"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[0.56 (0.29\u20131.11), 0.1]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "Household income (R)",
                "household income": ">100,000",
                "total number": "27",
                "percentage": "12.5%",
                "clustered": "10",
                "clustered percentage": "16.9%",
                "odds ratio": "1.04 (0.39\u20132.65)",
                "P-value": "0.93"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[1.04 (0.39\u20132.65), 0.93]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "CD4 cell count, cells/mm\u00b3",
                "CD4 cell count": ">500",
                "total number": "92",
                "percentage": "46%",
                "clustered": "30",
                "clustered percentage": "50.9%",
                "odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[1.0 (ref), \u2026]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "CD4 cell count, cells/mm\u00b3",
                "CD4 cell count": "\u2264500",
                "total number": "75",
                "percentage": "37.5%",
                "clustered": "19",
                "clustered percentage": "32.2%",
                "odds ratio": "0.70 (0.35\u20131.37)",
                "P-value": "0.31"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[0.70 (0.35\u20131.37), 0.31]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "CD4 cell count, cells/mm\u00b3",
                "CD4 cell count": "\u2264250",
                "total number": "15",
                "percentage": "7.5%",
                "clustered": "4",
                "clustered percentage": "6.8%",
                "odds ratio": "0.75 (0.2\u20132.4)",
                "P-value": "0.65"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[0.75 (0.2\u20132.4), 0.65]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "Major drug resistance mutation",
                "major drug resistance mutation": "No",
                "total number": "180",
                "percentage": "90%",
                "clustered": "55",
                "clustered percentage": "93.2%",
                "odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[1.0 (ref), \u2026]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "Major drug resistance mutation",
                "major drug resistance mutation": "Yes",
                "total number": "20",
                "percentage": "10%",
                "clustered": "4",
                "clustered percentage": "6.8%",
                "odds ratio": "0.57 (0.16\u20131.63)",
                "P-value": "0.33"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[0.57 (0.16\u20131.63), 0.33]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "HSV-2 infection",
                "HSV-2 infection": "No",
                "total number": "90",
                "percentage": "45%",
                "clustered": "25",
                "clustered percentage": "42.4%",
                "odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[1.0 (ref), \u2026]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "HSV-2 infection",
                "HSV-2 infection": "Yes",
                "total number": "69",
                "percentage": "34.5%",
                "clustered": "23",
                "clustered percentage": "39%",
                "odds ratio": "1.3 (0.65\u20132.57)",
                "P-value": "0.45"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[1.3 (0.65\u20132.57), 0.45]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "Ever pregnant",
                "ever pregnant": "No",
                "total number": "122",
                "percentage": "61%",
                "clustered": "37",
                "clustered percentage": "62.7%",
                "odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[1.0 (ref), \u2026]"
        },
        {
            "subject": {
                "study type": "HIV-infected study",
                "number of participants": "200",
                "characteristic": "Ever pregnant",
                "ever pregnant": "Yes",
                "total number": "49",
                "percentage": "24.5%",
                "clustered": "15",
                "clustered percentage": "25.4%",
                "odds ratio": "1.01 (0.48\u20132.06)",
                "P-value": "0.971"
            },
            "measures": "[odds ratio, P-value]",
            "outcomes": "[1.01 (0.48\u20132.06), 0.971]"
        }
    ]
}